JAACAP open · 2025
Does Combined Stimulant and Psychosocial Treatment in Childhood Attention-Deficit/Hyperactivity Disorder Protect Against Future Substance Use?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bommersbach Tanner J, Saliba Maria, Gilman Casey K, LeMahieu Allison, Tarikogullari Idil, Unlu Hayrunnisa, Utter Kierstin S, Sharma Pravesh, Romanowicz Magdalena, Abulseoud Osama
Аннотация
OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for future substance use. Stimulant medication has largely failed to demonstrate protection against future substance use, but no studies have assessed whether combined stimulant and psychosocial treatment reduces future substance use compared with stimulants alone.
METHOD: This retrospective study used data from the Rochester Epidemiology Project, a medical records repository in Olmsted County, Minnesota, to identify 1,541 children ≤7 years old who were prescribed a stimulant for ADHD between 2003 and 2019. Of children, 40% (n = 628) also received psychosocial treatment. Data on substance use after age 10 were gathered from the medical record until 2023, comprising up to 17 years of follow-up. Logistic regression compared substance use outcomes between the 2 treatment groups, and multivariable models identified childhood factors associated with future substance use.
RESULTS: Of 1,541 children with ADHD (median age = 6.0 years [interquartile range = 5.0, 7.0]; 1,111 [72%] boys, 1,225 [79%] White), 515 (33%) had documented substance use after age 10. Children who were older at initial treatment, had public insurance, had history of trauma, or had family history of substance use disorder diagnoses were more likely to use substances. Although children who received combined treatment were less likely than children who received stimulants alone to use tobacco/nicotine (21% vs 25%, adjusted odds ratio [aOR] = 0.86, p = .033), there was no significant difference in excessive alcohol use (aOR = 0.95, p = .49), any cannabis use (aOR = 0.88, p = .07), or other drug use (aOR = 0.82, p = .14).
CONCLUSION: One-third of children with ADHD went on to use substances. Combined stimulant and psychosocial interventions at baseline were associated with lower risk of tobacco/nicotine use, but there was no difference in other substance use.
METHOD: This retrospective study used data from the Rochester Epidemiology Project, a medical records repository in Olmsted County, Minnesota, to identify 1,541 children ≤7 years old who were prescribed a stimulant for ADHD between 2003 and 2019. Of children, 40% (n = 628) also received psychosocial treatment. Data on substance use after age 10 were gathered from the medical record until 2023, comprising up to 17 years of follow-up. Logistic regression compared substance use outcomes between the 2 treatment groups, and multivariable models identified childhood factors associated with future substance use.
RESULTS: Of 1,541 children with ADHD (median age = 6.0 years [interquartile range = 5.0, 7.0]; 1,111 [72%] boys, 1,225 [79%] White), 515 (33%) had documented substance use after age 10. Children who were older at initial treatment, had public insurance, had history of trauma, or had family history of substance use disorder diagnoses were more likely to use substances. Although children who received combined treatment were less likely than children who received stimulants alone to use tobacco/nicotine (21% vs 25%, adjusted odds ratio [aOR] = 0.86, p = .033), there was no significant difference in excessive alcohol use (aOR = 0.95, p = .49), any cannabis use (aOR = 0.88, p = .07), or other drug use (aOR = 0.82, p = .14).
CONCLUSION: One-third of children with ADHD went on to use substances. Combined stimulant and psychosocial interventions at baseline were associated with lower risk of tobacco/nicotine use, but there was no difference in other substance use.